AWMSG approve tapentadol m/r for restricted use
12th January 2012
The All Wales Medicines Strategy Group (AWMSG) has recommended tapentadol modified release (m/r) (Palexia® SR, Grunenthal, Buckinghamshire) as an option, within NHS Wales, for restricted use for patients with severe chronic pain in whom morphine sulphate m/r has failed to provide adequate pain control or is not tolerated.
The Group does not recommend tapentadol m/r for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics, outside of the subpopulation described above.
The Group also recommends that tapentadol m/r should initially be prescribed by a specialist.
Recent news
- Morphine manifesto
- EAPC guidelines on the use of opioid analgesics for cancer pain
- MHRA consult on loperamide classification from P to GSL
- Revised patient guide on advance care planning
- MHRA warns against Butterbur herbal remedies
- FDA approve generic morphine sulphate m/r capsules
- Discontinuation of granisetron (Kytril) infusion 1mg/mL
- SMC accepts fentanyl single dose nasal spray
- Crush resistant formulation of oxymorphone approved in US
- NICE end of life care commissioning guide
News archive
- 2012
- 2011
- 2010
- 2009
- 2008
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
- 2001
- 2000